Upstream Bio, Inc. (NASDAQ:UPB) Receives Average Recommendation of “Hold” from Brokerages

Posted by Geri Gentry on Jun 18th, 2026

Shares of Upstream Bio, Inc. (NASDAQ:UPB – Get Free Report) have earned an average rating of “Hold” from the seven brokerages that are currently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and four have given a buy recommendation to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $33.1667.

Several equities analysts have commented on UPB shares. Wall Street Zen lowered shares of Upstream Bio from a “hold” rating to a “sell” rating in a research report on Saturday, March 28th. JPMorgan Chase & Co. lowered shares of Upstream Bio from an “overweight” rating to a “neutral” rating and lowered their price objective for the company from $35.00 to $8.00 in a research report on Friday, June 12th. Mizuho lowered their price objective on shares of Upstream Bio from $51.00 to $50.00 and set an “outperform” rating for the company in a research report on Thursday, May 14th. Weiss Ratings lowered shares of Upstream Bio from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, May 6th. Finally, HC Wainwright started coverage on shares of Upstream Bio in a research report on Wednesday, June 3rd. They set a “buy” rating and a $36.00 price objective for the company.

Check Out Our Latest Stock Report on Upstream Bio

Upstream Bio Stock Performance

Shares of NASDAQ:UPB opened at $6.15 on Thursday. The firm has a fifty day moving average price of $8.57 and a 200 day moving average price of $16.30. Upstream Bio has a fifty-two week low of $5.85 and a fifty-two week high of $33.68. The firm has a market cap of $334.68 million, a price-to-earnings ratio of -2.11 and a beta of 1.10.

Upstream Bio (NASDAQ:UPB – Get Free Report) last released its quarterly earnings data on Wednesday, May 13th. The company reported ($0.75) EPS for the quarter, missing the consensus estimate of ($0.73) by ($0.02). Upstream Bio had a negative net margin of 4,718.96% and a negative return on equity of 43.82%. The business had revenue of $1.03 million for the quarter, compared to the consensus estimate of $1.03 million. As a group, research analysts predict that Upstream Bio will post -2.9 earnings per share for the current year.

Hedge Funds Weigh In On Upstream Bio

Several institutional investors have recently bought and sold shares of UPB. ADAR1 Capital Management LLC bought a new stake in shares of Upstream Bio in the 1st quarter worth about $315,000. California State Teachers Retirement System lifted its holdings in shares of Upstream Bio by 170.7% in the 1st quarter. California State Teachers Retirement System now owns 39,661 shares of the company’s stock worth $357,000 after acquiring an additional 25,009 shares during the last quarter. The Manufacturers Life Insurance Company lifted its holdings in shares of Upstream Bio by 51.2% in the 1st quarter. The Manufacturers Life Insurance Company now owns 15,338 shares of the company’s stock worth $138,000 after acquiring an additional 5,191 shares during the last quarter. Quantinno Capital Management LP lifted its holdings in shares of Upstream Bio by 220.4% in the 1st quarter. Quantinno Capital Management LP now owns 49,389 shares of the company’s stock worth $445,000 after acquiring an additional 33,974 shares during the last quarter. Finally, Entropy Technologies LP bought a new stake in shares of Upstream Bio in the 1st quarter worth about $210,000.

Upstream Bio Company Profile

(Get Free Report)

Upstream Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation prophylactic vaccines and immuno-oncology therapies. Leveraging a proprietary viral vector platform, the company aims to deliver optimized antigen payloads that stimulate robust and durable immune responses against both infectious diseases and cancer targets. Upstream Bio’s approach emphasizes safety, manufacturability and potential for rapid scale-up to address emerging public health challenges.

The company’s research and development pipeline includes multiple viral vector-based candidates in early clinical and preclinical stages.